Understanding breast cancer in young Latin American women
Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women (PRECAMA): a Multicenter Population-based Case-control Study
This study looks at the different types of breast cancer in young women from Latin America to see how lifestyle and other factors affect their risk and treatment outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Ages | 20 Years to 45 Years |
| Sex | Female |
| Sponsor | International Agency for Research on Cancer Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 13 sites (Barretos and 12 other locations) |
| Trial ID | NCT03144648 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the molecular subtypes of premenopausal breast cancer among women in Latin America. It focuses on identifying specific risk factors, tumor characteristics, and the impact of lifestyle factors such as diet and physical activity on breast cancer incidence and mortality. By conducting a multi-center case-control study, the research seeks to gather comprehensive data that can inform preventive measures and improve treatment outcomes for this demographic. The study will include women aged 20 to 45 who have been diagnosed with primary breast cancer.
Who should consider this trial
Good fit: Ideal candidates for this study are women aged 20 to 45 who have been diagnosed with primary breast cancer and have lived in the study area for at least three years.
Not a fit: Patients currently undergoing tumor treatment or those with chronic health conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and targeted prevention strategies for breast cancer in young women in Latin America.
How similar studies have performed: While there is limited research specifically targeting this demographic, similar studies have shown promise in understanding breast cancer risk factors in other populations.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * woman between 20 and 45 years old * woman less than 3 years older or younger than the case * living in the area that the study is taking place during the past 3 years * woman menstruated at least once in the past 12 months * woman diagnosed with a primary breast cancer by histopathological examination (only for cases) Exclusion Criteria: * woman receiving tumor treatment, such as radiotherapy, chemotherapy or anti-estrogens (for example, tamoxifen) (except treatment for non-melanoma skin cancers) * woman taking (or has previously taken) any of the following medications in the past 6 months: tamoxifen, Evista (raloxifene), Fareston (toremifene), Aromasin (exemestane), Femara (letrozole), Arimidez (anastrozole) or Megace (megestrol) * woman suffering from chronic kidney failure * woman having a pathology that will hinder adequate communication * woman who is pregnant or nursing * woman who has been previously diagnosed with a cancer(except for non-melanoma skin cancers) * any other reason to exclude
Where this trial is running
Barretos and 12 other locations
- Barretos Cancer Hospital — Barretos, Brazil (Completed)
- INC — Santiago, Independencia, Chile (Active_not_recruiting)
- Hso-Crsco — Santiago, Peñalolén, Chile (Active_not_recruiting)
- Falp — Santiago, Providencia, Chile (Active_not_recruiting)
- Grupo Infección y Cáncer. Universidad de Antioquia — Medellín, Antioquia, Colombia (Recruiting)
- International Hospital of Colombia — Bucaramanga, Bucaramanga, Colombia (Recruiting)
- Facultad de Medicina, Universidad del Norte — Barranquilla, Colombia (Completed)
- Hospital Internacional de Colombia Fundacion Cardiovascular de Colombia — Bucaramanga, Colombia (Recruiting)
- SENOSAMA foundation — Bucaramanga, Colombia (Recruiting)
- Instituto de Oncología HematoOncologos — Cali, Colombia (Completed)
- Public Health University of Narino — Pasto, Colombia (Recruiting)
- Agencia Costarricense de Investigaciones Biomédicas (ACIB) — San José, Provincia de San José, Costa Rica (Completed)
- Instituto Nacional de Salud Pública (INSP) — Cuernavaca, Morelos, Mexico (Completed)
Study contacts
- Principal investigator: Sabina Rinaldi, PhD — International Agency for Research on Cancer, Lyon, France
- Study coordinator: Sabina Rinaldi, PhD
- Email: rinaldis@iarc.who.int
- Phone: +33 472738485
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.